Race Oncology Ltd. ( (AU:RAC) ) has shared an announcement.
Race Oncology Ltd. is on the brink of several critical data and value inflection points with the imminent start of an open-label clinical trial for their drug RC220 this quarter. The company is increasing its focus on the health of cancer survivors and anticipates significant news flow throughout 2025, which is expected to drive positive sentiment in the sector.
More about Race Oncology Ltd.
Race Oncology Ltd. operates in the healthcare industry, focusing on cancer care. The company is known for its validated drug used in numerous clinical trials, demonstrating established safety and anti-cancer activity. They have developed an improved drug, RC220, which has been reformulated for easier administration and benefits from 20 years of intellectual property protection.
YTD Price Performance: -7.41%
Average Trading Volume: 86,537
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$217.2M
Find detailed analytics on RAC stock on TipRanks’ Stock Analysis page.